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Piebaldism is an autosomal dominant genetic disorder 
of pigmentation characterized by congenital patches 
of white skin and hair that lack melanocytes. Piebald­
ism resu�ts from mutations of the KIT proto-on90� 
gene, which encodes the cell-surface receptor trans­
membrane tyrosine kinase for an embryonic growth 
factor, Steel factor. Several pathologic mutations of 
the KIT gene have now been identified in dHferent 
P iebaldism is an autosomal dominant genetic disorder of melanocyte development characterized clinically by congenital patches of white skin (leukoderma) and white hair (poliosis), principally located on the scalp, forehead, ventral chest and abdomen, and extremities 
[1-3]. Unlike vitiligo, with which it is frequently confused, in 
piebaldism the depigmented patches are present from birth and are 
generally static in shape and distribution, although limited@ling in 
sometimes occurs, especially in milder cases. Hirschprung disease 
(aganglionic megacolon) is occasionally also present, but most af­
fected individuals display only the pigmentary anomaly. Piebaldism 
is relatively rare, although its actual frequency is not known. Be­
cause of its distinctive phenotype, piebaldism, sometimes incor­
rectly called I?artial albinism, has been known since at least ancient 
Greek times [4], and was one of the first autosomal dominant ge­
netic disorders recognized [5]. Piebaldism was also one of the first 
genetic disorders for which a pedigree was presented, and several 
families have been reported that trace inheritance of the disorder 
over hundreds of years (reviewed in [2]). Etymologically, pie appar­
ently refers to the variegated black and white plumage pattern char­
acteristic of the magpie, and bald derives from the Greek phalios, 
having a white spot. Histologically, the depigmented patches lack 
most or all melanocytes [6,7], although areas of increased pigmenta­
tion may occur at the boundaries of or even within the regions of 
hypopigmentation. Melanocytes derive embryologically from the 
neural crest, and piebaldism has thus been considered to be a lin­
eage-specific disorder of neural crest development, most likely in­
volving defective melanoblast proliferation, migration, or survival. 
The critical clues to elucidation of the molecular basis of human 
piebaldism came from studies of a similar disorder of mice, domi­
nant white spotting (W). Mouse dominant white spotting, which is 
associated with defects of pigmentation, hematopoiesis, and germ­
cell development (reviewed in [8,9]), was found to result from dele­
tions or point mutations of the c-kit protooncogene (reviewed in 
[10]. The c-kit gene, originally identified in the genome of the 
HZ4-feline sarcoma virus [11], encodes the cell-surface receptor for 
an embryonic growth factor. This growth factor, which has been 
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patients with piebaldism. Correlation of these muta­
tions with the associated piebald phenotypes has led to 
the recognition of a hierarchy of three classes of muta­
tions that result in a graded series of piebald pheno­
types, and to improved understanding of the mecha­
nisms that underlie dominant genetic disorders. Key 
worth: KIT/receptor/tyrosine kinase/growth/actor.] Invest 
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variously called mast cell growth factor, stem cell factor, KL (kit 
ligand), or Steel factor (SLF) (reviewed in [10]), is the product of the 
steel (SI) locus of mice, and both SI and W mutant mice display 
similar piebald-like phenotypes. 
The human piebaldism locus was tentatively mapped to chromo­
some segment 4q12 on the basis of several patients with piebaldism 
associated with de novo chromosomal translocations or deletions 
involving this region [12 - 15]. Subsequently, the human KIT gene 
was mapped to approximately the same chromosomal location 
[16,17], suggesting that human piebaldism might, like mouse dom­
inant white spotting, also result from abnormalities of the KIT 
gene. Our confirmation of this hypothesis, the subsequent identifi­
cation of a variety of pathologic mutations of the KIT gene in 
different families with piebaldism, and the correlation of these spe­
cific mutations with the resultant clinical phenotypes has proved 
highly instructive of the biology of the Steel-KIT system of signal 
transduction. 
BIOLOGY OF THE KIT RECEPTOR 
The KIT protein is a member of the type III group of transmem­
brane receptor tyrosine kinases. As illustrated in Fig 1, the KIT 
polypeptide consists of an amino-terminal extracellular ligand­
binding receptor domain composed of five immunoglobulin-type 
repeats, a short transmembrane domain, and an intracellular domain 
consisting of a bipartite tyrosine kinase domain followed by a car­
boxy-terminal tail. The stoichiometry of interaction between Steel 
factor and the extracellular ligand-binding domain of the KIT re­
ceptor is not certain, but is thought to be monovalent [18]. How­
ever, on binding the Steel factor ligand, the KIT receptor undergoes 
dimerization within the cell membrane [18] (reviewed in [10]) , 
activating its intracellular tyrosine kinase. This, in turn, results in 
autophosphorylation of specific tyrosine residues within the KIT 
kinase domain, enhancing the binding of various proteins, includ­
ing phosphatidylinositol 3' kinase and phospholipase Cyl, which 
act as downstream mediators of the mitogenic signal in the KIT -de­
pendent pathway of signal transduction (reviewed in [10)). 
The human KIT structural gene consists of 21 exons distributed 
over more than 70 kb (kilobases) at chromosome segment 4q12 
[19,20], adjacent to the closely related PDGFRA and KDR genes, 
which encode similar type III receptor tyrosine kinases for different 
polypeptide growth factors. The first exon of the KIT gene encodes 
the translational initiation codon and an apparent signal peptide 
[19], and the last exon principally encodes the very long 3' -untrans-
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Figure 1. Schematic diagram of the human KIT polypeptide and 
both published and unpublished mutations that are associated with 
human piebaldism. The amino-terminal extracellular leader sequence 
(LS) and penta-repetitive ligand binding domain, the transmembrane do­
main (TM), and the intracellular bi-partite tyrosine kinase domain are indi­
cated. Missense amino acid substitutions are indicated by solid circles, frame­
shifts by solid djamonds, splice junction mutations by djagonal slashes, and a 
nonsense mutation by X. 
lated region of KIT mRNA. The KIT mRNA precursor is alterna­
tively spliced at exon 9, resulting in the production of a minor 
976-amino acid KIT polypeptide and a predominant 972-amino 
acid polypeptide lacking residues 510 to 513 [19]. The same general 
gene structure [21] and alternative splicing of KIT mRNA also 
occur in the mouse, and the two alternative isoforms of the mouse 
KIT receptor exhibit distinctly different properties in the absence of 
exogenous Steel factor [22]. The intracellular tyrosine kinase do­
main is the most highly evolutionarily conserved segment, both 
within the KIT polypeptide itself and among a wide variety of 
different tyrosine kinases from a diverse array of species. As ex­
pected, KIT mRNA is expressed by human melanocytes , although 
expression of KIT appears to frequently be down-regulated in mela­
nomas [23]. The KIT receptor is also expressed in brain, placenta, 
gut, erythroid stem cells of the bone marrow, mast cells, breast, and 
in the gonads. 
MUTATION OF THE KIT GENE 
IN HUMAN PIEBALDISM 
To test the hypothesis that human piebaldism might result from 
abnormalities of the KIT gene, we first studied a patient with pie­
baldism, mental retardation, and multiple congenital anomalies as­
sociated with a de novo interstitial deletion of segment q12-q21.1 of 
chromosome 4 [15]. By means of quantitative Southern blot hybrid­
ization analyses we showed that this deletion included both the KIT 
and adjacent PDGFRA genes [24]. Thus, this patient was hemizy­
gous for a chromosomal segment that spans both of these loci. 
Fleischman and coworkers [25] likewise described a similar patient 
with deletion of both the KIT and PDGFRA genes, although this 
deletion was not detectable cytogenetically. The deletions in these 
two patients thus appeared homologous to the W19H deletion of 
mouse, which also includes both the KIT and PDGFRA genes, and 
strongly supported the hypothesis that human piebaldism and 
mouse Ware homologous. 
To determine whether human piebaldism can also result from' 
point mutations of the KIT gene, we defined the organization and 
nucleotide sequence of the human KIT gene and characterized its 
DNA sequence in a series of patients with typical autosomal domi­
nant piebaldism . To do this, we amplified all 21 exons of the KIT 
gene from genomic DNA by use of the polymerase chain reaction 
(PCR) and initially subjected the amplified products to complete 
DNA sequence analysis . More recently, we have utilized PCR­
based single-stranded conformation polymorphism (SSCP)/heter­
oduplex analysis to localize mutations to specific KIT exons prior to 
DNA sequencing. As shown in Fig 1, 10 different point mutations 
of the KIT gene have now been reported in different families with 
piebaldism, as well as several additional mutations not yet pub-
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lished. These mutations can be classified into three general groups� 
each group tending to be associated with piebald phenotypes of 
differing severity. Thus, a hierarchical paradigm of pathologic 
human KIT mutations appears to account for a graded seties of 
dominant phenotypes in human piebaldism. 
The first group of KIT gene mutations consists of missense su� 
stitutions that result in amino acid substitutions, all of which are 
located within the intracellular tyrosine kinase domain. Five such 
mutations have been reported, Glu583Lys [26], Phe584Leu [27], 
Gly664Arg [28], Arg791Gly [29], and Gly812Val [29], almost all 
involving amino acid residues that have been especially highly con_ 
served during mammalian evolution. Moreover, the locations of 
several of these human KIT missense substitutions correspond very 
closely to the positions of similar mutations that have been identi­
fied in various strains of W mutant mice (reviewed in [IO]) (the 
human Glu583Lys mutation corresponds precisely to the mouse 
W17 mutation), providing further evidence of the importance of 
these spots to function of the KIT receptor. These five human KIT 
missense substitutions are all associated with relatively severe pie­
bald phenotypes. This is a consequence of the fact that the KIT 
kinase is only activated on dimerization of the receptor. In patients 
heterozygous for KIT missense mutations one-fourth of the KIT 
receptor dimers contain only the abnormal KIT polypeptide, which 
are inactive. However, half of the KIT receptor dimers consist of 
one normal KIT polypeptide and one abnormal KIT polypeptide; 
these heterodimers are also inactive. Thus, patients heterozygous 
for these so-called dominant-negative KIT missense mutations have 
only one-fourth of the normal amount of KIT receptor , and accord­
ingly they exhibit relatively severe piebald phenotypes. 
In contrast, the second group of KIT mutations completely elimi­
nate the production of KIT protein by the mutant gene. Patients 
heterozygous for these so-called loss of function mutant alleles thus 
express half of the normal amount of KIT receptor. Apparently, 
however, half of the normal amount of receptor is not adequate, 
resulting in haploinsufliciency for KIT-dependent signal transduc­
tion. These KIT mutations are thus associated with relatively mild 
piebald phenotypes, in which the depigmented patches are usually 
small and poliosis is often absent, although affected individuals fre­
quently experience early graying of the hair. In fact, some members 
of families with KIT mutations of this type have been so mildly 
affected that the clinical diagnosis was only made subsequent to 
DNA diagnosis. We have described two such different mutations, 
both frameshifts located very proximal in the KIT gene, at codon 85 
[30] and at codons 250-251 [31]. Interestingly, we identified the 
same codon 250 -251 frameshift in three different, unrelated fami­
lies with mild piebaldism [31]. This apparently recurrent KIT gene 
mutation may account for a significant fraction of human piebald­
ism, especially among clinically milder cases. 
The third group of patients with piebaldism exhibit a very vari­
able phenotype, ranging from extremely mild to quite severe, even 
among affected members of an individual family. We have de­
scribed three KIT mutations of this type, two frameshifts [27] and a 
splice junction mutation [30], which would all result in premature 
termination of translation, truncating the nascent KIT polypeptide 
distally, within the intracellular tyrosine kinase domain. Clearly, 
these mutations abolish expression of normal KIT polypeptide from 
,this allele. However, the truncated KIT receptor apparently can still 
bind Steel factor and even form dimers, dominant negatively inhib­
iting function of the normal KIT polypeptide [18]. It is likely, 
however, that both the truncated KIT polypeptides and the incom­
pletely translated KIT mRNA are relatively unstable. Therefore, 
these mutations probably reduce KIT receptor function to an 
amount between one-fourth and half of normal, accounting for the 
intermediate and highly variable piebald phenotype. 
Interestingly, the only amino acid substitution we have observed 
within the extracellular ligand-binding domain of the KIT receptor 
appears to be a rare non-pathologic variant (unpublished data). As 
noted above, this region consists principally of five immunoglobu­
lin-like domains, and it is possible that this segment may be at least 
in part functionally redundant. Thus, many amino acid substitu-
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tions in this portion of the KIT polypeptide may have little or no 
effect on ligand binding, and thus may have little or no phenotypic 
effect. However, the extracellular portion of the KIT polypeptide is 
also thought to contain the segments that mediate receptor dimeri­
zation, and it seems likely that pathologic amino acid substitutions 
of residues involved in this process may be encountered in the fu­
ture. 
Thus, piebaldism is associated with reduced expression of the 
KIT receptor, resulting in decreased KIT-dependent signal trans­
duction and abnormal distribution of melanoblasts during embryo­
logic development. Recent evidence indicates that reduced expres­
sion of KIT likely results in decreased proliferation of melanoblasd 
during emoryologic development [32]. { 
ARE THERE OTHER HUMAN PIEBALDISM GENES? 
Overall, we have been able to identify pathologic point mutations 
of the KIT gene in approximately two-thirds of the more than thirty 
unrelated patients with typical piebaldism we have studied to date, 
and several more appear to have deletions that include part of all of 
KIT (unpublished data). However, in about one-fourth of patients 
we can find no apparent abnormalities of the KIT gene. Some of 
these patients may have occult KIT gene mutations not detected by 
SSCP /heteroduplex screening; however, in at least several of these 
patients we have also not found any abnormalities by complete 
DNA sequence analysis. Interestingly, none of these patients have 
abnormalities of the MGF gene (the formal name for the human 
Steel factor gene), suggesting that, in contrast with mice, mutations 
of this gene may not result in the piebald phenotype in humans . 
Furthermore, we have conducted genetic linkage analyses in several 
of these families, and in all of these the piebald trait was completely 
linked to the KIT gene (unpublished data). Together, these data 
suggest that most or all of these patients either have occult muta­
tions (or deletions) in the KIT gene not detected by our analyses or 
that they have mutations in a nearby gene also required for normal 
developmental patterning of melanocytes. What might constitute a 
second human piebaldism gene in this region? We have recently 
isolated and mapped a contig of human recombinant yeast artificial 
chromosomes (YACs) spanning the entire human PDGFRA-KIT­
KDR type III receptor tyrosine kinase gene cluster. covering more 
than 2 megabases of DNA in chromosome segment 4q12 (33). In 
mouse, the patch (Ph) mutation, which results in a dominant white 
spotting pheno!=>,'pe similar to that of W, coml'rises a deletion that 
includes the pdgJra gene but not c-kit [24,35j. It is not yet clear 
whether white spotting in patch mice results from deletion of the 
pdgfra gene itself or from inhibitory effects of the large chromo­
soMal deletion on expression of the nearby c-kit gene. Thus, it 
remains possible that some cases of human piebaldism may result 
from mutations in the PDGFRA gene or other genes in this region 
that have yet to be identified. 
RELATED PROBLEMS 
In addition to piebaldism, abnormalities of the Steel factor-KIT 
pathway of signal transduction have been implicated in two other 
disorders. Longley and coworkers [36] recently reported aberrant 
expression of the Steel factor ligand in patients with cutaneous 
mastocytosis. This disorder is associated with both mast cell prolif­
eration and increased skin pigmentation, and it is likely that both of 
these symptoms result from increased or inappropriate stimulation 
of the Steel-KIT - dependent pathway of signal transduction. Ab­
normalities of the Steel-KIT system have also been sought in pa­
tients with Diamond-Blackfan anemia, a heterogeneous group of 
clinically severe congenital hypoplastic anemias. In addition to 
characteristic white parches, W mutant mice with c-kit mutations 
frequently exhibit a hypoplastic anemia similar to that of humans 
with Diamond-Blackfan anemia. However, humans with piebald­
ism do not have anemia f37]. and several investigators have failed to 
find abnormalities of either the KIT or MGF genes in patients with 
Diamond-Blackfan anemia [38-40]. Thus, these genes no longer 
are viable candidate genes for this disorder. 
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